Abstract
Beta3-adrenoreceptors (B3AR) are traditionally known as metabolic receptors in adipose tissue, but came into focus in the cardiovascular field after our demonstration of their expression in human cardiac myocytes and endothelial cells, where they mediate endothelium-dependent relaxation of coronary resistance vessels through production of both nitric oxide and endothelium-dependent hyperpolarization factor(s) (EDHF). B3AR are also expressed at the plasma membrane of rodent and human cardiac myocytes. Notably, their expression is increased in several forms of human cardiomyopathies, which raises questions about their adaptive or maladaptive role in myocardial remodelling. To test the hypothesis that they may counteract the adverse effect of B1-B2-AR overactivation, we set out to study the cardiac phenotype of transgenic mice expressing human recombinant B3AR under the cardiac-specific alpha-MHC promoter. While exhibiting no apparent phenotype at basal state, these mice seem protected from hypertrophic remodeling under a variety of stresses, without developing left ventricular dysfunction. Notably, this protection seems to depend on a functional nitric oxide synthase (NOS), as it is abrogated under NOS inhibition. These features can all be recapitulated in homotypic cardiac myocytes cultures in vitro. B3AR transgenic mice may also be protected from fibrosis through a paracrine cross-talk to cardiac fibroblasts. These data suggest a beneficial role of B3AR in myocardial remodeling through attenuation of fibrosis and of excessive cardiac myocyte hypertrophy, while at the same time optimizing perfusion. As B3AR are resistant to homologous desensitization, they are attractive targets for therapeutic interventions in the setting of chronic sympathetic stimulation, as it is prevalent in heart failure and several cardiomyopathies.
Keywords: Beta3-adrenergic receptor, Human, Catecholamines, Heart Failure, Hypertrophy, Myocardial remodeling, Nitric Oxide
Current Drug Delivery
Title:Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Volume: 10 Issue: 1
Author(s): Jean-Luc Balligand
Affiliation:
Keywords: Beta3-adrenergic receptor, Human, Catecholamines, Heart Failure, Hypertrophy, Myocardial remodeling, Nitric Oxide
Abstract: Beta3-adrenoreceptors (B3AR) are traditionally known as metabolic receptors in adipose tissue, but came into focus in the cardiovascular field after our demonstration of their expression in human cardiac myocytes and endothelial cells, where they mediate endothelium-dependent relaxation of coronary resistance vessels through production of both nitric oxide and endothelium-dependent hyperpolarization factor(s) (EDHF). B3AR are also expressed at the plasma membrane of rodent and human cardiac myocytes. Notably, their expression is increased in several forms of human cardiomyopathies, which raises questions about their adaptive or maladaptive role in myocardial remodelling. To test the hypothesis that they may counteract the adverse effect of B1-B2-AR overactivation, we set out to study the cardiac phenotype of transgenic mice expressing human recombinant B3AR under the cardiac-specific alpha-MHC promoter. While exhibiting no apparent phenotype at basal state, these mice seem protected from hypertrophic remodeling under a variety of stresses, without developing left ventricular dysfunction. Notably, this protection seems to depend on a functional nitric oxide synthase (NOS), as it is abrogated under NOS inhibition. These features can all be recapitulated in homotypic cardiac myocytes cultures in vitro. B3AR transgenic mice may also be protected from fibrosis through a paracrine cross-talk to cardiac fibroblasts. These data suggest a beneficial role of B3AR in myocardial remodeling through attenuation of fibrosis and of excessive cardiac myocyte hypertrophy, while at the same time optimizing perfusion. As B3AR are resistant to homologous desensitization, they are attractive targets for therapeutic interventions in the setting of chronic sympathetic stimulation, as it is prevalent in heart failure and several cardiomyopathies.
Export Options
About this article
Cite this article as:
Balligand Jean-Luc, Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor, Current Drug Delivery 2013; 10 (1) . https://dx.doi.org/10.2174/1567201811310010011
DOI https://dx.doi.org/10.2174/1567201811310010011 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry Human Myoblast Genome Therapies and Devices in Regenerative Medicine
Recent Patents on Regenerative Medicine Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Chemistry and Biology of Gluten Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle
Current Genomics Cell Sheet Technology for Heart Failure
Current Pharmaceutical Biotechnology Inflammation, Oxidation, Caloric Expenditure and Cognitive Impairment in Brazilian Elderly Assisted at Primary Care
Current Alzheimer Research Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets